FDA Fast Track for ADX-2191 in retinitis pigmentosa at Aldeyra (NASDAQ: ALDX)

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its product candidate ADX-2191 for the treatment of retinitis pigmentosa, a serious eye disease that can lead to vision loss. This designation is intended to facilitate the development and expedite the review of drugs that address unmet medical needs. The company disclosed this information through a press release dated August 19, 2025, which is attached as an exhibit to the report.

Positive

• FDA Fast Track Designation granted for ADX-2191 in retinitis pigmentosa, a potentially important step that can expedite development and review for this indication.

Negative

• None.

Insights

Biotech & Regulatory Strategy Analyst

FDA Fast Track status for ADX-2191 is a potentially meaningful regulatory milestone for Aldeyra.

The company states that the U.S. Food and Drug Administration granted Fast Track Designation to ADX-2191 for treating retinitis pigmentosa. Fast Track is an FDA program designed to speed the development and review of drugs targeting serious conditions with unmet medical need, which can streamline interactions with the agency.

For Aldeyra, this designation may allow more frequent communication with the FDA and eligibility for accelerated review pathways if certain criteria are met. The disclosure is limited to the fact of designation; it does not discuss clinical data, timelines, or commercial terms, so the ultimate impact will depend on future development progress and subsequent regulatory steps.

0001341235false00013412352025-08-192025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

ALDEYRA THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

Delaware		001-36332		20-1968197
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (781) 761-4904

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		ALDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 19, 2025, Aldeyra Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) to announce that the U.S. Food and Drug Administration has granted Fast Track Designation for ADX-2191 for the treatment of retinitis pigmentosa. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Aldeyra Therapeutics, Inc. Press Release dated August 19, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALDEYRA THERAPEUTICS, INC.
By:	/s/ Todd C. Brady
	Name: Todd C. Brady M.D., Ph.D.
	Title: Chief Executive Officer

Dated August 19, 2025

FAQ

What regulatory update did Aldeyra Therapeutics (ALDX) report?

Aldeyra Therapeutics reported that the U.S. Food and Drug Administration granted Fast Track Designation for its product candidate ADX-2191 for the treatment of retinitis pigmentosa.

Which Aldeyra Therapeutics drug received FDA Fast Track Designation?

The product candidate ADX-2191 received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of retinitis pigmentosa.

What disease area is targeted by Aldeyra’s ADX-2191 Fast Track program?

ADX-2191 has been granted FDA Fast Track Designation for the treatment of retinitis pigmentosa, a serious eye disease associated with progressive vision loss.

How did Aldeyra disclose the Fast Track Designation for ADX-2191?

Aldeyra disclosed the designation in a report stating that it issued a press release dated August 19, 2025, which is filed as Exhibit 99.1 and incorporated by reference.

Who signed the Aldeyra Therapeutics report about the Fast Track Designation?

The report was signed on behalf of Aldeyra Therapeutics, Inc. by Todd C. Brady, M.D., Ph.D., who is identified as the company’s Chief Executive Officer.